Cargando…

Personalized Management in Low-Risk Prostate Cancer: The Role of Biomarkers

Current criteria to predict low-risk prostate cancer (PCa) are still subject to discussion as a substantial number of PCa patients who progress to a more aggressive disease seem to be missed, using these criteria. The main challenge in PCa diagnosis, therefore, is to distinguish patients with low-ri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dijkstra, Siebren, Hamid, Agus Rizal A. H., Leyten, Gisèle H. J. M., Schalken, Jack A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532864/ https://www.ncbi.nlm.nih.gov/pubmed/23304520 http://dx.doi.org/10.1155/2012/327104

Ejemplares similares

Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy
por: Armandari, Inna, et al.
Publicado: (2014)

The need for a personalized approach for prostate cancer management
por: Sedelaar, JP Michiel, et al.
Publicado: (2015)

PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis
por: Salagierski, Maciej, et al.
Publicado: (2010)

Epigenetic markers in circulating cell‐free DNA as prognostic markers for survival of castration‐resistant prostate cancer patients
por: Hendriks, Rianne J., et al.
Publicado: (2018)

Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis
por: Matuszczak, Milena, et al.
Publicado: (2021)

Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer
por: Hamid, Agus Rizal A. H., et al.
Publicado: (2021)

Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI
por: Leyten, Gisele H. J. M., et al.
Publicado: (2013)

How accurate is our prediction of biopsy outcome? PCA3-based nomograms in personalized diagnosis of prostate cancer
por: Salagierski, Maciej, et al.
Publicado: (2012)

Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports
por: Minnee, Pieter, et al.
Publicado: (2019)

Noncoding RNAs as Novel Biomarkers in Prostate Cancer
por: Rönnau, C. G. H., et al.
Publicado: (2014)

Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis
por: Visser, Wieke C. H., et al.
Publicado: (2020)

The impact of obesity towards prostate diseases
por: Parikesit, Dyandra, et al.
Publicado: (2016)

Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer
por: Visser, Wieke C. H., et al.
Publicado: (2022)

Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis
por: Afriansyah, Andika, et al.
Publicado: (2018)

Cystoscopy-assisted laparoscopic partial cystectomy for muscle-invasive bladder cancer: Initial experience in Cipto Mangunkusumo Hospital, Jakarta
por: Hafizar, et al.
Publicado: (2021)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Surgical Management of Giant Genital Condyloma Acuminata by Using Double Keystone Flaps
por: Eriad Yunir, Peri, et al.
Publicado: (2016)

Imaging as a Personalized Biomarker for Prostate Cancer Risk Stratification
por: Gennaro, Kyle H., et al.
Publicado: (2018)

Personalized Cancer Therapy for Urological Cancers: From Bench to Bedside and Back
por: Uemura, Hirotsugu, et al.
Publicado: (2012)

Management of bilateral Wilms’ tumour: A case report
por: Wahyudi, Irfan, et al.
Publicado: (2020)

Zero ischaemia open partial nephrectomy using Thulium laser in pediatric renal tumor: A first experience
por: Yunanto, Angling, et al.
Publicado: (2018)

Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia
por: Putra, Ida Bagus O.W., et al.
Publicado: (2016)

The Expression of Transforming Growth Factor Beta-1 and Interleukin-6 on Human Prostate: Prostate Hyperplasia and Prostate Cancer
por: Afdal, Afdal, et al.
Publicado: (2019)

Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature
por: Yausep, Oliver E., et al.
Publicado: (2019)

Carbon sources and pathways for citrate secreted by human prostate cancer cells determined by NMR tracing and metabolic modeling
por: van Heijster, Frits H. A., et al.
Publicado: (2022)

Case of perinephric abscess disguising as renal tumor
por: Raharja, Putu Angga Risky, et al.
Publicado: (2018)

Personalized schedules for surveillance of low‐risk prostate cancer patients
por: Tomer, Anirudh, et al.
Publicado: (2018)

Label retention and stem cell marker expression in the developing and adult prostate identifies basal and luminal epithelial stem cell subpopulations
por: Ceder, Jens Adam, et al.
Publicado: (2017)

Blood Transfusions in Laparoscopic Living Donor Nephrectomy: Single Center Experience from 500 Cases
por: Boentoro, Senohadi, et al.
Publicado: (2020)

Retroperitoneoscopic proximal ureter resection and ureteroureterostomy as an alternative management for upper tract urothelial carcinoma: A case report
por: AH Hamid, Agus Rizal, et al.
Publicado: (2021)

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2023)

Prostate cancer biomarkers and multiparametric MRI: is there a role for both in prostate cancer management?
por: Saltman, Anna, et al.
Publicado: (2021)

The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate—a long-term follow-up comparison and quality of life analysis
por: Dijkstra, Siebren, et al.
Publicado: (2016)

MRI for managing intermediate & low risk prostate cancer
por: Padhani, Anwar R
Publicado: (2014)

Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer
por: Choe, Kevin S., et al.
Publicado: (2010)

Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis
por: Luna Velez, Maria V., et al.
Publicado: (2019)

Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients
por: Hamid, Agus Rizal A. H., et al.
Publicado: (2020)

Adenocarcinoma mucinosum of extrophy bladder: A rare case report
por: Hamid, Agus Rizal A.H., et al.
Publicado: (2021)

The Role of Targeted Focal Therapy in the Management of Low-Risk Prostate Cancer: Update on Current Challenges
por: Smith, Daniel W., et al.
Publicado: (2012)

Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?
por: Yap, Timothy A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_oqpnonio3ib218cpisobiuh9n7